Skip to content
MRD Watch

Wednesday, November 18, 2026

Subscribe
Sponsor this briefing. One site and newsletter slot, $250/week.

Briefing

ctDNA guiding adjuvant immunotherapy in urothelial carcinoma.

In the IMvigor010 correlative analysis, 214 of 581 evaluable people were ctDNA-positive and had a poor prognosis; atezolizumab improved disease-free and overall survival in that group and not in the ctDNA-negative group.

NaturePubMed 34135506DOI 10.1038/s41586-021-03642-9